MedTrace Logo

DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

NCT00899548 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 182

Last updated 2019-07-26

Study results available
· View outcomes & findings →

Summary

RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to systemic therapy.

PURPOSE: This laboratory study is looking at DNA in predicting response after systemic therapy in women with metastatic breast cancer.

Conditions

Interventions

GENETIC

DNA methylation analysis

laboratory analysis

GENETIC

microarray analysis

laboratory analysis

GENETIC

polymerase chain reaction

laboratory analysis

OTHER

laboratory biomarker analysis

laboratory analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Antonio C. Wolff, MD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-06-30
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00899548 on ClinicalTrials.gov